Can AI Help Pick the Best IVF Embryo?

Embryo selection is one of the most important decisions in IVF. When more than one embryo is available, the care team has to decide which embryo appears most likely to implant and lead to a healthy pregnancy. That process has traditionally depended on trained embryologists reviewing embryo development and grading what they see. It is a skilled process, but it also involves judgment calls, especially when several embryos look similar.

That is one reason artificial intelligence has drawn so much attention in fertility care. AI systems can analyze embryo images, time-lapse development patterns, and in some cases patient clinical information to help predict embryo quality and pregnancy outcomes. The promise is appealing: more consistency, less subjectivity, and potentially better decision support. But the key question is not whether AI sounds impressive. It is whether the evidence is strong enough to trust it in real-world clinical care.

Why embryo selection matters so much in IVF

A successful IVF cycle depends on far more than embryo selection alone, but embryo choice is still a critical step. If multiple embryos are available, selecting the most promising one first may improve the chance of implantation while avoiding unnecessary transfers. It can also shape decisions about freezing, future treatment planning, and whether additional testing may be useful.

This is a difficult task because embryos that look similar under the microscope do not always behave the same way. Traditional grading relies on careful observation of morphology, timing, and developmental features, but even highly trained embryologists can differ in how they interpret subtle visual differences. That does not mean the human process is unreliable. It means the process is inherently complex, and small differences in interpretation can matter.

AI is being studied as a tool to support this step by identifying patterns that may be difficult for the human eye to weigh consistently across many embryos and many cycles. In theory, that could make embryo ranking more standardized and more data-driven.

What the 2023 systematic review found

A 2023 systematic review in Human Reproduction Open compared AI-assisted embryo selection with standard embryologist assessment. The review included 20 studies and found that AI consistently outperformed clinical teams in the studies focused on embryo morphology and clinical outcome prediction. Across the included studies, AI models generally showed higher median accuracy than embryologists when predicting embryo quality or the likelihood of clinical pregnancy.

One of the most interesting findings was that the strongest-performing models were often the ones that combined embryo images or time-lapse data with clinical information about the patient or treatment cycle. In that subgroup, the review reported a higher median accuracy for AI than for embryologists, suggesting that AI may be particularly useful when it can evaluate embryo appearance together with broader clinical context instead of relying on images alone.

The review also helps explain why AI has generated so much interest. If embryo selection is partly limited by human subjectivity, then a model trained on large datasets may be able to apply its scoring criteria more consistently from case to case. That does not automatically mean it is ready to replace human judgment, but it does mean the research signal is strong enough to take seriously.

How AI may reduce subjectivity without replacing expertise

The most realistic near-term role for AI in IVF is not as a replacement for embryologists, but as decision support. Embryologists bring laboratory expertise, clinical context, and practical judgment that a model does not fully replicate. At the same time, AI may help reduce variation when embryos appear nearly identical or when subtle developmental differences are difficult to rank consistently.

That combination could be valuable. A strong AI system may help flag embryos with higher predicted implantation potential, while the embryology team still interprets that output within the full context of the patient, the lab, and the treatment plan. In other words, the best question may not be “human or AI?” but “how should clinical teams use AI well, if at all?”

This matters for patients too. New technology is often presented as automatically better, but that is not a serious standard. Patients deserve to know whether a tool has been validated, what outcomes it was trained to predict, and whether it has been shown to perform well outside the center where it was developed.

Why more clinical validation is still needed

The same systematic review that highlighted AI’s promise also pointed to major limits. Many models were built using local datasets, and many lacked external validation. The paper also noted that AI had diffused into IVF development work without prospective verification against embryologists using real-world data. That is a meaningful caution, not a minor footnote.

In practice, this means a strong result in retrospective research does not automatically guarantee the same benefit in day-to-day clinic use. Different labs, imaging systems, patient populations, grading approaches, and culture conditions may all affect how well a model generalizes. The review also found study heterogeneity and concerns around bias and generalizability, which makes it harder to treat the published numbers as universally transferable.

There is another important nuance: the review argues that future work should focus less on narrow short-term outcomes like implantation alone and more on outcomes such as ongoing pregnancy or live birth. That is the right standard. A tool that looks accurate on a limited prediction task is not necessarily improving the outcome patients care about most.

What patients should take from this now

AI in embryo selection is not science fiction, and it is not empty hype either. The research suggests it may become a meaningful tool for improving consistency and supporting embryo ranking, especially when image-based assessment is combined with relevant clinical information. At the same time, the evidence still does not justify treating AI as a settled standard that every patient should expect every clinic to use.

That is where Her Serenity’s approach matters. Patients deserve clear, honest information without pressure. A thoughtful conversation is not just “Does this clinic use AI?” but also “What does the tool actually do?”, “Has it been validated in real clinical practice?”, and “How does it fit into the judgment of the embryology and physician team?” Those questions slow the conversation down in the best way. They help patients make choices based on evidence and fit, not marketing.

The right takeaway is balanced: AI may help embryo selection become more accurate and less subjective, but the current evidence still points to a need for broader prospective testing, stronger validation, and careful clinical implementation before it should be treated as routine standard care.